Clonal Diversity of Cancer Cells

Image for post
Image for post
DNA barcode strategy to examine plasticities across clones. DNA barcodes, stably introduced into cells, can be used to track the progeny of individual cells. Sorting these cells, and quantifying the abundance of each barcode in both cell states, will distinguish if clones vary in phenotypic plasticity. Included in the schematic is a Sanger sequence trace of the pool of barcode plasmids. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356442/#!po=8.82353
Image for post
Image for post

2019 John A. Catanzaro

Clonal diversity of cancer cells associated with immune evasion, escape, invasive progression and drug resistance characteristically exhibit phenotypic heterogeneity. This results in part from the ability of the cancer cells to switch between phenotypic states. In other words, change in identity (progeny to progeny). Change in antigenic determinant expression creating tolerance and resistance. https://lnkd.in/fJDHfkK

The diversity of cancer cell phenotypes within individual tumors plays a major role in driving immune evasion, escape, invasive progression and drug resistance. Individual cancer cell mutation and migratory patterns are also driving forces to the diversity of the tumor microenvironment. In support of this model, there are significant genetic differences between different sections of a tumor, and even across different cells from the same tumors. https://lnkd.in/fw8EmZD

Image for post
Image for post

DNA barcoding to track phenotypical changes and label a diverse catalogue of clone varieties to assess changes in cell type and tumor patterns can interrogate changing plasticities. https://lnkd.in/fJnjGSf https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356442/#!po=8.82353

Cancer Hallmark Analytics and Immunocentric engineering integrates interrogation profiling to determine cancer cell and tumor microenvironment behavior and changes for downstream patient precision-based treatment immune innovation.

Image for post
Image for post

#cancer #dna #genomesequencing #proteomics #cancerimmunotherapy #immunooncology #peptides #molecularbiology #genetics

John A. Catanzaro is CEO of Neo7logix, a bioscience company that designs precision and personalized treatment designs. www.neo7logix.com

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store